

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Elaine Alison IRVING et al.

International Application No.: PCT/EP2004/01016

International Filing Date: February 2, 2004

For: Therapeutical Use of Anti-Myelin Associated Glycoprotein (MAG) Antibodies

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed
☐ Copies of the references were submitted in parent application Serial No. _____.
(37 CFR 1.98(d))
☒ A copy of the International Search Report which issued on International Application No. PCT/EP2004/01016 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 as Item Nos. 1, 2, 5, 6, 11, and 18 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

Express Mail Label No.: EV332065774US

Date of Mailing: 9/19/05

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown above.

Patty Wilson
Patty Wilson


JC20 Rec'd PCT/PTO 19 SEP 2005

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- ☒ Please charge any required fees to Deposit Account No.07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Virginia G. Campen
Attorney of Record
Registration No. 37,092

Date: 19 Sept. 05
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1012
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	SERIAL NO.	10/550363
	FILING DATE	
	APPLICANT	IRVING et al.
	GROUP	
	EXAMINER	
ATTORNEY DOCKET NO.		PB60024USw

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continue on page

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
1.	WO 95/53945	10/28/1999	PCT			
2.	WO 95/22344	8/24/1995	PCT			
3.	WO 97/01352	1/16/1997	PCT			
4.	WO 97/07810	3/6/1997	PCT			
5.	WO 02/062383	8/15/2002	PCT			
6.	WO 04/014953	2/19/2004	PCT			

Continue on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

7.	CHOTHIA et al., Conformations of Immunoglobulin Hybervariable Regions, Nature 342:877-883 (1989).
8.	DEBELLARD et al., Myelin-Associated Glycoprotein Inhibits Axonal Regeneration from a Variety of Neurons via Interaction with a Sialoglycoprotein, Molecular and Cellular Neuroscience 7:89-101 (1996).
9.	IRVING et al., Rapid Alteration of Tau in Oligodendrocytes after Focal Ischemic Injury in the Rat: Involvement of Free Radicals, J. of Cerebral Blood Flow & Metabolism 17:612-622 (1997).
10.	LASSMANN et al., Dying-Back Oligodendroglialopathy: A Late Sequel of Myelin-Associated Glycoprotein Deficiency, GLIA 19:104-110 (1997).
11.	NIEDEROST et al., Nogo-A and Myelin-Associated Glycoprotein Mediate Neurite Growth Inhibition by Antagonistic Regulation of RhoA and Rac1, J. of Neuroscience 22(23):10368-10376 (2002).
12.	POLTORAK et al., Myelin-Associated Glycoprotein, a Member of the L2/HNK-1 Family of Neural Cell Adhesion Molecules, Is Involved in Neuron-Oligodendrocyte and Oligodendrocyte-Oligodendrocyte Interaction, J. of Cell Biology 105:1893-1899 (1987).
13.	TANG et al., Soluble Myelin-Associated Glycoprotein (MAG) Found <i>in Vivo</i> Inhibits Axonal Regeneration, Molecular and Cellular Neuroscience 9:333-346 (1997).
14.	TORIGOE et al., Selective Inhibition of Early Axonal Regeneration by Myelin-Associated Glycoprotein, Experimental Neurology 150:254-262 (1998).
15.	UMEMORI et al., Initial events of myelination involve Fyn tyrosine kinase signaling, Nature 367:572-576 (1994).
16.	VALERIANI et al., Quantitative Assessment of Ischemic Pathology in Axons, Oligodendrocytes, and Neurons: Attenuation of Damage After Transient Ischemia, J. of Cerebral Blood Flow & Metabolism 20:765-771 (2000).
17.	VINSON et al., Lipid rafts mediate the interaction between myelin-associated glycoprotein (MAG) on myelin and MAG-receptors on neurons, Molecular and Cellular Neuroscience 22:344-352 (2003).
18.	WONG et al., A p75 ^{NTR} and Nogo receptor complex mediates repulsive signaling by myelin-associated glycoprotein, Nature Neuroscience 5(12):1302-1306 (2002).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.